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Non-medical initiatives to decrease venous ulcers
prevalence
Marc A. Passman, MD, on behalf of writing group IV of the Pacific Vascular Symposium 6,
Birmingham, AlaWith the stated goal of Pacific Vascular Symposium 6
(PVS6) “to produce a plan of action aimed to decrease the
prevalence of venous ulcers by 50% in 10 years,” the scope
of the non-medical issues working group (Group IV) was
to identify and prioritize critical issues to achieve this goal
outside usual evidence-based medical-knowledge-based
analysis. Diverse expertise within Group IV included past
and current American Venous Forum and Society for Vas-
cular Surgery leadership, interest in public awareness and
education, experience with governmental relations, a rep-
resentative from insurance regulatory commission, and rep-
resentation from industry involved in venous disease. While
the other groups focused on current evidence surrounding
deep venous thrombosis and postthrombotic disease
(Group I), primary chronic venous disease (Group II), and
ulcer healing and recurrence (Group III), Group IV ad-
dressed more global issues of venous ulcer prevention and
treatment, and in this respect was intertwined across many
topics discussed by the other groups. The purpose of the
current review is to summarize the proceedings from
Group IV discussion, identifying critical non-medical issues
that represent challenges to achieving the stated goal of
venous ulcer reduction and to provide recommendations
for implementation of global action plans to achieve the
stated goal.
CRITICAL ISSUE 1
Lack of awareness of venous ulcer recognition,
diagnosis, treatment, and prevention at all levels of
the health care system
Background. A health care system (HCS)1 is a com-
plex network of agencies, facilities, organizations, and
trained personnel engaged in providing health care within a
specified geographical area, which may be limited to a
single hospital-based system or extend to the national level.
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doi:10.1016/j.jvs.2010.05.071Within an integrated HCS triangle, there is a managed care
system that includes a hospital organization that provides
acute patient care, a multispecialty medical care delivery
system, the capability of contracting for any other needed
services, and a payer, all of which provide health care
services to enrollees of the health care plan.
In the treatment of chronic diseases, such as venous
ulcers, there is involvement in patient care at all levels of the
HCS. In contrast to a few decades ago when patients with
venous ulcers often involved inpatient hospital care, today
much of this care has shifted to outpatient settings and
home environments, with HCS relying on health care
providers, nursing personnel, and patient or family mem-
bers to provide venous ulcer care.
Although emphasis on venous ulcer care has shifted
within theHCS, and evidence exists on effective prevention
and treatment of venous ulcers, there is still a gap in
implementation of these measures. Much of this gap in-
volves lack of awareness regarding venous ulcer recogni-
tion, diagnosis, effective treatment measures, and preven-
tion at all levels of the HCS tree. This disparity further
reflects different priorities at each level of the HCS regard-
ing venous ulcer care, as well as problems with integrating
care across all of these levels.
Evidence. Analogous to need to increase awareness
regarding venous ulcer care is the recent effort to increase
awareness for venous thromboembolism (VTE) prophy-
laxis. VTE has been known to be a significant problem in
hospitalized patients for many years. A recent search of the
National Guideline Clearinghouse (www.guideline.gov)
revealed approximately 100 guidelines on VTE prevention,
including the most authoritative guideline in the field, the
well-referenced, evidence-based, clinical practice guidelines
from the American College of Chest Physicians (ACCP)
published in 2008.2 Nevertheless, evidence-based guide-
lines and recommendations for VTE prevention have been
underused across HCSs, reflecting the challenge of trans-
lating evidence supporting VTE prevention into clinical
practice across a range of health care settings. In recogni-
tion of this gap, significant efforts have been made over the
past decade to increase awareness regarding VTE by quality
accreditation organizations, an awareness trend further re-
inforced by The Surgeon General’s Call to Action to Prevent
Deep Vein Thrombosis and Pulmonary Embolism issued on
September 15, 2008,3 leading to VTE prevention becom-
ing a mandated health care quality measure.
Also learned from the VTE awareness efforts has been
the variable degree of effectiveness of quality improvement
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sures. A systematic review of 30 studies between 1996 and
2003 in hospitalized patients showed that passive dissemi-
nation of VTE prophylaxis guidelines was unlikely to im-
prove compliance. Instead, active strategies that incorpo-
rate reminders to clinicians to assess patients for VTE risk
and include information on proper selection of a prophy-
lactic measure were most likely to be successful.4 This
observation was reinforced further in the 2008 ACCP
guidelines, which noted that passive strategies, which in-
clude activities such as distribution of guidelines or single
educational events, are not effective, while multi-component
approaches, audit and feedback, and the use of automatic
reminders such as preprinted orders and computer remind-
ers are highly successful.
Highlighting other successful efforts to increase aware-
ness regarding venous disease is the AmericanVenous Forum,
NationalVenous ScreeningProgram (AVF-NVSP).Despite a
considerable wealth of knowledge acquired over the past
few decades regarding venous diseases, a significant propor-
tion of physicians, allied health personnel, health care ad-
ministrators, and the lay public continue to be conspicu-
ously unaware of these advances. Recognizing this gap, the
American Venous Forum established the AVF-NVSP in
2005 with the mission of increasing awareness of venous
disease through identification of those at risk, educational
interactions, and empowerment to inform others about
venous disease.5 AVF-NVSP educational efforts have also
included venous screening performed directly on health
care providers, which increases awareness about venous
disease through improved identification of venous disease
in participant’s health care practice settings.6 As of 2010,
the AVF-NVSP now includes a comprehensive screening
program for VTE risk and chronic venous insufficiency, a
focused VTE risk screening program, printed educational
material for health care providers and the general public, risk
assessment screening at the hospital entry level, and online
venous screening educational initiatives.
Discussion. Group discussion highlighted several chal-
lenges to closing the gap in venous ulcer recognition,
diagnosis, treatment, and prevention within HCSs includ-
ing: 1) Recognition of the many different HCSs in the
United States, each with their own limitations, priorities,
and extent of care plan coverage; 2) Identification of the
many levels within each HCS, with different educational
needs; 3) Scope and practicality of any educational effort
instituted should be appropriately defined to increase
awareness about venous ulcer care at different levels of the
HCS; and 4) Any educational effort to improve venous
ulcer awareness and care may be limited by resources and
finances.
Although challenges exist, the group recognized that
there are current models of integrated health care systems
already in place that may allow pilot implementation of
venous ulcer prevention and treatment educational pro-
grams. Cited examples included Vermont Blueprint for
Health (http://healthvermont.gov/blueprint.aspx), Mayo
Health System (http://www.mayohealthsystem.org/mhs/live/page.cfm), Kaiser Permanente (https://www.
kaiserpermanente.org/), and integrated health care initia-
tives through the United States Department of Veterans
Affairs (http://www1.va.gov/health/). Once these pro-
grams are implemented, then their wider dissemination
into other integrated HCSs would follow.
Conclusions.
● There is a gap between venous ulcer awareness and
current evidence that has created a challenge for ve-
nous ulcer prevention and treatment algorithms;
● All levels of HCS from payer to patients to health care
provider will need to be addressed with educational
programs to improve venous ulcer disease awareness.
Recommendations.
● Develop educational programs targeting all levels of
health care system, especially at the patient and primary
care levels;
● Implement smaller scale models to prove efficacy of
educational/awareness efforts within current inte-
gratedHCSs before wider expansion into largerHCSs.
Action and follow-up. Several action plan items were
recommended by the group to increase awareness about
venous ulcer recognition, diagnosis, treatment, and pre-
vention, including: 1) Expansion of current educational
programs such as those available through AVF to medical/
nursing schools, graduate medical education, and health
care providers currently in practice; 2) Use of focused
venous disease screening programs as an educational effort
for the general public and health care providers; and 3)
Development of online educational programs on venous
diseases and ulcer care. Once these educational programs
are in place, development of pilot implementation pro-
grams within current integrated HCS would occur first,
followed by expansion of these educational protocols into
larger HCSs. Follow-up of effectiveness would include
measurements of awareness pre- and postimplementation
via survey data or continuing medical education-based pro-
grams at different levels of the health care system.
Proposed timeline. One to two years to develop edu-
cational programs; 2 to3 years implementation pilot program;
3 to 4 years impact follow-up after implementation.
CRITICAL ISSUE 2
Variable quality of care for venous ulcers because of
poor coordination of care within all levels of the
health care system and lack of standard guideline
implementation and compliance
Background. Evidence-based guidelines for preven-
tion and treatment of venous ulcers exist, but the problem
of too many guidelines from too many different sources
makes implementation difficult. While current guidelines
may address some portions of theHCS, integration of these
guidelines into all levels of the HCS is lacking.
Evidence. Examples of current evidence-based guide-
lines for venous ulcer prevention and treatment include:1 1)
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Aid the Healing of Venous Ulcers, 20107; 2) Smith and
Nephew, Ltd., Leg Ulcer Guidelines: A Pocket Guide for
Practice, 20028; 3) Association for the Advancement of
Wound Care, Summary Algorithm for Venous Ulcer care
with Annotations of Available Evidence, 20059; 4) Scottish
Intercollegiate Guidelines Network (SIGN), Update of
SIGN 26 The care of patients with Chronic Venous (Leg)
Ulcers, 200910; 5) Royal College of Nursing Institute, The
management of patients with venous leg ulcers, 1998-
Updated 200611; 6) Canadian Association of Wound Care,
Best Practices for the Prevention and Treatment of Venous
Leg Ulcers, 200112; 7) Wound, Ostomy, and Continence
Nurses Society, Guideline for management of wounds in
patients with lower-extremity venous disease 200513; 8)
American Society of Plastic Surgeons, Chronic wounds of
the lower extremity 200714; 9) Registered Nurses’ Associ-
ation of Ontario, Assessment and management of venous
leg ulcers, 200415; and 10) Handbook of Venous Disor-
ders: Guidelines of the American Venous Forum, 3rd
Edition.16
While several evidence-based guidelines exist, efforts at
integrated implementation into all levels of the HCS have
been variable. Highlighted by groups such as the Associa-
tion for the Advancement of Wound Care (AAWC) Gov-
ernment and Regulatory Task Force, there has been the
creation of content-validated venous ulcer guidelines based
on objective summaries of best available evidence support-
ing venous ulcer care that attempts to align the language,
practice, and reimbursement of venous ulcer care, but
wider application has not occurred.
As a successful model of an integrated venous ulcer care
prevention and treatment pathway, the group exemplified
the recent efforts in Skaraborg County, Sweden, where,
based on the results of a 1988 cross-sectional epidemiolog-
ical study establishing leg ulcer point prevalence, a com-
plete change in the care of leg ulcer patients was brought
into practice. Based on clinical examination, an assessment
of the underlying causes of ulceration was made. The study
showed a 23% decrease in leg ulcer prevalence (2.4/1000
population in 2002 compared with 3.1/1000 in 1988).
Venous insufficiency was still the dominating causative
factor, although the number of patients with venous leg
ulcers was reduced by 46%. The authors concluded that the
observed reduction in point prevalence of venous ulcers
reflected the introduction of the change in management
strategy undertaken in the area.17
Discussion. The critical challenge identified by the
group underlying variable quality of care for venous ulcers
and lack of coordination of care within different levels of
HCS is the presence of too many guidelines from too many
sources. While some of these are evidence-based, most are
clinical practice guideline formats, and prospective valida-
tion is usually limited.18 Furthermore, a major part of
evidence-based guidelines only address a narrow focus
within most HCSs. Without consensus and coordination,
wider implementation into complex and diverse HCSs is
problematic.Conclusions.
● Although guidelines for prevention and treatment of
venous ulcers exist, there are toomany guidelines from
many different sources, making coordinated integra-
tion into HCSs difficult;
● The need to unify evidence-based guidelines is critical
in order to facilitate implementation into complex and
diverse HCSs;
● Evidence-based guidelines need to address all levels of
HCSs.
Recommendations.
● Create unified evidence-based multidisciplinary mod-
els for venous ulcer prevention and treatment that
address and coordinate all levels of HCS;
● Target smaller scale HCS models to prove efficacy of
evidence-based guideline implementation efforts, be-
fore expansion into larger HCSs.
Action plan and follow-up. The group proposed an
evidence-based care model that would: 1) Identify portals
of venous ulcer patient entry; 2) Create simple clinical
assessment recommendations; 3) Use clinical referral algo-
rithms to include specialists with vascular and wound ex-
pertise but also extend to all levels of HCS. The following
process was suggested: 1) Identify existing guidelines for
review, revision, and consolidation; 2) Invite multi-spe-
cialty and multi-society collaboration to participate in new
guideline creation; 3) Disseminate guidelines by print and
electronic media to targeted medical doctors, registered
nurses, physician’s assistants, advanced registered nurse
practitioners, and other health care providers functioning at
portals of entry for venous ulcer, but also extend these
guidelines to incorporate other levels of HCS that are
needed to support venous ulcer prevention and treatment.
To facilitate expansion of evidence-based guidelines for
venous ulcer care, an active Electronic Health Record
(EHR) interface would need to be developed specific to
venous ulcer prevention and treatment algorithms. Imple-
mentation of these model venous ulcer prevention and
treatment programs into integrated HCS should occur
initially on a pilot smaller scale level, but should then
extend to the national level (examples: Veterans Affairs
[VA] system, Centers of Medicare and Medicaid Services
[CMS]), state level (example: Vermont Blueprint for
Health), regional level (example: Mayo), and insurance
carrier level (examples: Blue Cross Blue Shield, Kaiser).
Follow-up of the effectiveness of this plan would include
creation and dissemination of guidelines into HCS mod-
els, with measurement of volume of diagnosed venous
disease, venous ultrasound testing, venous wound care,
and venous procedures in HCS before and after imple-
mentation of evidence-based multi-tiered guidelines.
Proposed timeline. One to two years to consolidate
current evidence-based guidelines, 2 to 3 years for care
model development and expansion, and 3 to 5 years for
wide implementation.
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Poorly substantiated economics of prevention and
treatment of venous ulcers leading to problems in
determining cost effective quality care and optimal
reimbursement
Background. High-quality data that accurately assess
the total economic burden of venous thrombembolism,
venous insufficiency, and venous ulceration, both sepa-
rately and as a continuum, are lacking. In general, this gap
in economic data for venous disease is a reflection of the
overall complexities of health care economics in the United
States as a whole. Individual decisions about best health
care by practitioners are often challenged by optimal pro-
vision of health care services and availability of health care
resources, at the same time being affected by the overall
United States economic and health care policy issues.
Evidence. The economics of prevention and treat-
ment of venous ulcers is currently overshadowed by more
global United States health care economic issues. Current
figures estimate that spending on health care in the United
States is approximately 16% of the Gross Domestic Product
(GDP). In 2007, an estimated $2.26 trillion was spent on
health care in the United States, or $7439 per capita.
Health care costs are rising faster than inflation, and
the health share of GDP is expected to continue its upward
trend, reaching 19.5 percent of GDP by 2017. In fact,
government health care spending in the United States is
consistently greater, as a portion of GDP, than all other
western developed countries, while at the same time, ac-
cording to the Insitute of Medicine of the National Acad-
emy of Sciences, being the “only wealthy, industrialized
nation that does not ensure that all citizens have cover-
age.”19 This disparity between the high cost of health care
and questions of universal access to health care, have led to
ongoing calls for health care reform in the United States.
The estimated total cost of VTE in the United States is
$3.2 billion to $15.5 billion per year.20 Estimates from the
Agency for Healthcare Research and Quality (AHRQ)
Healthcare Cost and Utilization Projects put incremental
inpatient costs at $10,000 per DVT and $20,000 per
pulmonary embolism (PE).21 Based on a per-case basis, a
recent study found that the median annualized direct med-
ical costs during and after a DVT or PE event were $17,512
and $18,901 per patient, respectively.22 Another estimate
indicated that postoperative VTE complications added an
average of $18,310 to total hospital costs for each affected
patient.23 Costs are substantial in part because of the high
incidence of VTE and its complications. Given the epide-
miologic estimates of the current incidence of VTE and the
high costs per patient, the economic burden of VTE on the
health care system may be much higher than previously
thought. In addition, this is not just confined to the diag-
nosis and treatment of the initial event. An estimated 7% to
13% of patients with an initial VTE event will have a
recurrence within 1 year, and approximately 30% will have
a recurrence within 5 years.24The estimated economic cost of treating venous ulcers
approaches 1% of the health care budget of Western Euro-
pean Countries.1,25 Although the majority of patients with
venous ulcers can be treated on an outpatient basis and are
infrequently hospitalized except for complications, the di-
rect cost of treating venous ulcers in the United States
averages $2500 per month per patient. In the outpatient
setting, the direct cost of venous ulcer care is related to
professional reimbursement, cost of wound care treat-
ments, and specialized wound dressings that often include
compression based therapy, with healing rapidity being one
of the most important determinants.
Discussion. The group discussion highlighted several
challenges in determining cost-effective quality care for
prevention and treatment of venous ulcers. Overall health
care economics is confusing, with different priorities exist-
ing at all levels of the HCS. While health care providers are
concerned with the most effective evidence-based venous
ulcer care, health care payers and policy makers are more
concerned with cost containment, sometimes at the ex-
pense of quality. This disparity makes health care econom-
ics and policy influenced more by non-medical factors
contributing to CMS policy. While better economic data
relating to venous ulcer care and prevention are needed,
there is a lack of interest at all levels of the HCS to obtain
these specific data.
Conclusions.
● Optimal cost-effective quality of care for prevention
and treatment of venous ulcers is lacking, and better
economic data are needed.
Recommendations.
● Develop unbiased economic data to help convince
governmental agencies, payers, and other stakeholders
in the HCS on the value equation involved in venous
ulcer prevention and quality care.
Action plan and follow-up. The group proposed
partnering with health economic institutions to help navi-
gate the complicated health care economic field. With
better understanding of health care economic priorities,
better sources of economic data for venous ulcer preven-
tion and treatment can be obtained. Venous ulcer cost-
effective data could result in a higher level of participation
in health care policy determination (see Critical Issue 5).
Examples of participation in venous ulcer care policy mak-
ing should also include presentation at health care payer
meetings such as the National Association of Insurance
Commissioners (NAIC, http://naic.org/). Additional
partnership with industry while avoiding conflicts of inter-
est may also help to achieve economic goals of cost-effective
quality venous ulcer care. Follow-up would include analysis
and dissemination of economic data showing favorable
reimbursement algorithms for venous ulcer care prevention
and treatment.
Proposed timeline. One to two years to obtain and
disseminate economic data, 3 to 4 years to impact venous
ulcer care reimbursement.
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Funding for research in venous ulcer prevention and
treatment is currently limited and studies on
comparative effectiveness lacking
Background. National Institutes of Health (NIH)
funding opportunities for research on venous ulcer preven-
tion and treatment have been limited in the past, with
current ongoing clinical trials funded mostly by non-NIH
sources. This disparity in funding sources has created a gap
between research implementation and much needed com-
parative effectiveness data.
Evidence. Search of the NIH website (http://
grants1.nih.gov/grants/oer.htm) for both active and inac-
tive Request for Applications (RFA) and Program An-
nouncements (PA), revealed specific funding opportunities
for “venous ulcers” to be limited: past RFA-AR-94-001
(1993) for “Failure to Heal: Chronic Wound Healing in
the Skin” (http://grants.nih.gov/grants/guide/rfa-files/
RFA-AR-94-001.html); and past RFA-HL-05-014 (2004)
for “Critical Issues in Post-Phlebitic Syndrome” (http://
grants.nih.gov/grants/guide/rfa-files/RFA-HL-05-014.
html). Review of NIH RFAs for search word “venous
thrombosis” revealed 18 funding opportunities between
1992 and 2007, most recently RFA-HL-08-002 (2007)
“Deep Venous Thrombosis and Venous Disease” (http://
grants.nih.gov/grants/guide/rfa-files/RFA-HL-08-002.
html), all of which preceded the Surgeon General’s Call to
Action to Prevent Deep Vein Thrombosis and Pulmonary
Embolism on September 15, 2008. A concurrent search of
ClinicalTrials.gov website (http://www.clinicaltrial.gov/
ct2/home) for “venous ulcers” listed 80 ongoing regis-
tered trials, most of which were funded through industry
sponsors.
At another national level, the Institute of Medicine of
the National Academies (IOM; http://www.iom.edu/),
in response to the American Recovery and Reinvestment
Act of 2009, recommended a list of priorities to be the
initial focus of a national investment in comparative effec-
tiveness research. In the IOM’s 100 Initial Priority Topics
for Comparative Effectiveness Research26 is a priority to
“compare the effectiveness of topical treatments (eg, anti-
biotics, platelet-derived growth factor) and systemic thera-
pies (eg, negative pressure wound therapy, hyperbaric ox-
ygen) in managing chronic lower extremity wounds.”
Within the scope of this priority is venous ulcer prevention
and treatment research opportunity. The list provides a
starting point for what should be a sustained effort to
conduct research comparing treatment options for venous
ulcers with the goal of adoption of results by health care
providers and organizations, and integration into clinical
practice. In response to the IOM’s priority topics, research
funding opportunities are becoming available through or-
ganizations like the AHRQ, although these are still limited
for studies on venous ulcer prevention and treatment.
Discussion. Challenges identified by the group in-
cluded recognition of NIH funding barriers, and competi-
tion among a wide variety of IOM comparative effective-ness research initiatives. Although there is identification of
chronic lower extremity wounds in the IOM list of priori-
ties, venous ulcer is only one of many listed priorities
competing for funding with other types of chronic lower
extremity wounds. Within these currently limited funding
opportunities for venous ulcer prevention and treatment,
there is a lack of a centralized coordinated funding effort
(see Critical Issues 5 and 6).
Conclusions. In order to develop studies on compar-
ative effectiveness for venous ulcer prevention and treat-
ment, additional research funding opportunities will be
required.
Recommendations. Develop a strong robust central-
ized foundation (see Critical Issue 6) to promote research
funding opportunities through NIH, industry, grant foun-
dations, and other alternative sources for studies on com-
parative effectiveness of venous ulcer prevention and
treatment.
Action plan and follow-up. Recommendations by
the group emphasized improved coordinated efforts at
approaching NIH and AHRQ for funding opportunities,
creation of an AVF government relations committee (see
Critical Issue 5) directed at NIH and AHRQ, correspond-
ing AVF grant writing support assistance, and reorganiza-
tion of the American Venous Forum Foundation (AVFF)
to include an independent funding board are feasible op-
tions to facilitate these and other funding sources. Fol-
low-up parameters include AVF committee and AVFF re-
structuring with the ultimate objective of funded projects
from targeted sources.
Proposed timeline. One to two years AVF and AVFF
restructuring, 3 to 5 years funded projects, completed
projects 5-10 years, new technology 10 years.
CRITICAL ISSUE 5
Improving the care of venous ulcers requires
understanding and input into health care policy
Background. The United States Congress and federal
regulatory agencies, such as CMS and the Food and Drug
Administration (FDA), make many critical decisions on
issues that have an impact upon health care providers and
their patients. With so many participants and stakeholders
in health care, determinants of health care policy are com-
plex. Improving quality measures for venous ulcer preven-
tion and treatment will require improved understanding of
policy formation processes and partnership with health care
policy makers.
Evidence. There are several examples of health policy
and government relations advocacy groups connected with
medical society and non-profit health care organizations.
The Society for Vascular Surgery (SVS) infrastructure in-
cludes:
● Director of Health Policy and Government Relations
to handle important policy issues;
● SVS Clinical Practice Council, involved in helping SVS
influence health care policymaking through advocacy
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and meeting with officials at CMS;
● SVS Political Action Committee, to facilitate reaching
United States Senators and Representatives who are
making decisions about our practices (http://www.
vascularweb.org/professionals/Government_Relations/
index.html).
The American College of Surgeons has a full-time
Advocacy and Health Care Policy Staff (http://www.facs.
org/ahp/index.html) and has created an affiliated not-for-
profit corporation, the American College of Surgeons Pro-
fessional Association (ACSPA), which, among many func-
tions, includes formation of a political action committee
that will work to improve the legislative and regulatory
climate in which surgeons practice.
Effective advocacy for VTE prevention has been in
evolution over the past decade and represents a model that
could be used to promote venous ulcer prevention and
treatment. The Institute of Medicine’s landmark report in
199927 on medical errors brought to public attention that
failure to provide prophylactic therapy for VTE when indi-
cated is a hospital error. That report has become the impe-
tus for subsequent VTE quality measures. Several overlap-
ping initiatives by quality care organizations including the
National Quality Forum (NQF; http://www.qualityforum.
org/), the Surgical Care Improvement Project (SCIP;
http://qualitynet.org/), the Joint Commission (http://
www.jointcommission.org/), and AHRQ (http://www.
ahrq.gov), have led to VTE prevention becoming a man-
dated health care quality measure. However, the challenge
of translating evidence supporting VTE prevention into
clinical practice extends across a range of health care set-
tings, and implementation of appropriate evidence-based
measures is still problematic. In recognition of this gap, a
workshop on VTEwas held at the NIH in Bethesda, MD in
May 2006. At the conclusion of the workshop, a Surgeon
General’s Call to Action was proposed by Dr Carmona to
provide a mechanism for the development of a coordinated
plan to address the lack of understanding and knowledge
that exists regarding VTE despite improvements in preven-
tion, diagnosis, and treatment.28 The resulting Surgeon
General’s Call to Action to Prevent Deep Vein Thrombosis
and Pulmonary Embolism delivered by Acting Surgeon
General, Rear Admiral Steven K. Galson, MD, MPH, and
Elizabeth G. Nabel, MD, Director National Heart, Lung,
and Blood Institute (NHLBI), National Institutes of
Health (NIH), on September 15, 2008, as an example of
advocacy was intended “to serve as a stimulus for the
development of a coordinated plan to reverse the current
trend and dramatically reduce the morbidity and mortality
caused by (deep vein thrombosis/pulmonary embolism).”
Discussion. The group identified several challenges to
attaining input into health care policy for venous ulcer
prevention and treatment, including the confusing land-
scape and time-consuming nature of health care policy
making, resource limitations, and need for committed phy-sicians interested in health care policy interactions directed
at venous ulcer care.
Conclusions.
● Input into health care policy will be required in order
to improve venous ulcer prevention and treatment.
Recommendations.
● Development of governmental relationships and advo-
cacy strategies will be needed in order to provide input
into health care policies addressing venous ulcer pre-
vention and treatment goals.
Action plan and follow-up. The group proposed the
following key strategies for improved health policy and
government relations directed at venous ulcer care:
● Creation of AVF Government Relations Committee
analogous to SVS, but with the focused mission of
addressing venous disease related issues;
● Request for assistance by SVS, ACS, and other active
medical societies and/or not-for-profit organzations
to help establish AVF relationships with governmental
agencies;
● Identification of interested leader(s) to function as a
liaison between AVF and governmental agencies ad-
dressing health care policy;
● Expansion of financial resources through AVFF and
AVF,Development Council. Follow-upmeasures would
include attaining the above initiativeswithAVF represen-
tation in governmental policy agencies.
Proposed timeline. One to two years committee for-
mation and leadership identification; 5 to 10 years estab-
lished direct relationship with governmental agencies;
funding ongoing.
CRITICAL ISSUE 6
Need for a strong central organization to promote
prevention and treatment of venous ulcers
Background. Several organizations interested in ve-
nous disease exist, but only some of these include venous
ulcer within the scope of their mission. Similarly, al-
though there are several evidence-based guidelines for
the prevention and treatment of venous ulcers (see Crit-
ical Issue 2), not all are promoted by interested organi-
zations. The net result is a poorly coordinated effort
across many interested organizations regarding venous
ulcer prevention and treatment.
Evidence. Current examples of organizations and med-
ical societies with a primary interest in venous disease include
American Venous Forum (AVF; http://www.veinforum.
org), Venous Disease Coalition (VDC; http://www.
venousdiseasecoalition.org/), and American College of
Phlebology (ACP; http://www.phlebology.org/). How-
ever, most of these organizations have a broad-based inter-
est in venous disease that covers both venous thrombotic
and venous insufficiency-related issues. Major vascular so-
cieties such as Society for Vascular Surgery (SVS; http://
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eties (http://www.vascularweb.org/Affiliated_Societies/
index.html) incorporate venous disease as part of the
overall scope of vascular diseases. Societies such as Wound
Healing Society (WHS; http://www.woundheal.org), As-
sociation for the Advancement of Wound Care (AAWC;
http://aawconline.org/), American Academy of Derma-
tology (AAD; http://www.aad.org/), and American Soci-
ety of Dermatology (ASD; http://asd.org/) include ve-
nous ulcer care issues within the scope of other nonvascular
interests. However, what is missing among all of these
organizations is a centralized effort to address venous ulcer
prevention and treatment, and thus far, there has been a
lack of success with current societal relationships to create a
unified approach and process.
Discussion. The group identified the need for a strong
central organization to promote prevention and treatment
of venous ulcers as the most important non-medical critical
issue. However, several challenges exist based on the scope
of current interested organizations which do not yet align
with the objectives of PVS6: To produce a plan of action
aimed to decrease the prevalence of venous ulcers by 50%
in 10 years. While there are different societies interested in
venous disease, not all of these societies are interested in
venous ulcer. On the other side, different societies are
interested in wound care, but not necessarily in venous
disease. For the objective of PVS6 to be met, a strong
coordinated effort will be required, but achieving this uni-
fied approach may be resource-limited.
Conclusions. To reach the goal of venous ulcer reduc-
tion, a strong central organization will be needed to pro-
mote all necessary elements required for venous ulcer pre-
vention and treatment.
Recommendations.
● Develop central infrastructure to promote importance
of prevention and treatment of venous ulcers.
Action plan and follow-up. The group recom-
mended an AVF action plan to organize and lead a multi-
society effort, with the specific aim of reducing venous ulcer
prevalence by improved venous ulcer prevention and treat-
ment. Financial support would need to be obtained
through the AVFF and AVF Development Council.
Follow-up would include alignment of AVF committee
creation, implementation, and action with follow-up status
reporting to the AVF Executive Council on an annual basis.
Proposed timeline. One to three years.
CONCLUSIONS
In order to achieve the stated objective of PVS6, “to
produce a plan of action aimed to decrease the prevalence of
venous ulcers by 50% in 10 years,” a coordinated effort will be
required. While the other groups at PVS6 focused on current
evidence surrounding DVT and postthrombotic disease
(Group I), primary chronic venous disease (Group II), and
ulcer healing and recurrence (Group III), Group IV ad-
dressed the more global non-medical issues of venous ulcer
prevention and treatment with a particular challenge ofimplementation of many topics discussed by the other
groups. The six critical issues outlined above provide the
framework for proceeding forward in a coordinated fash-
ion, most important of which will be a strong infrastructure
to promote the importance of prevention and treatment of
venous ulcers and a centralized dedicated organization to
monitor progress in achieving these goals.
PVS6 writing group IV members: Steve Elias, MD,
Monika Gloviczki, MD, PhD,Mike Dalsing, MD, James S.
Gardner, MD, MBA, Fedor Lurie, MD, PhD, Stephen
Mascioli, MD, MPH, TomO’Donnell, MD, Peter Pappas,
MD, Sandra Shaw, BA, MA, Bob Zwolak, MD.
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